Invention Summary: Rutgers scientists have developed a short route to chemically synthesize highly functionalized 14-membered macrolides, including those related to erythromycin and the ketolides. Previously, macrolides (e.g. erythromycin, azithromycin) were prepared semi-synthetically, which severely limited the scope of structural research and evaluation of the macrolide. This method of macrolide synthesis creates little to no restriction on the structure of the final target, which removes the bottleneck on creating new macrolide drug candidates. As the macrolide family includes antibiotics, antivirals, antifungals, immunosuppressants, and anticancer agents, these findings constitute a major advance in the macrolide drug discovery process. Advantages: Synthesis allows highly versatile products; Potential products promote novel drug discovery and optimization; Potential macrolide products could overcome drug-resistant disease. Market Applications: Therapeutics; Antiinfectives; Antibacterial Chemistry; Antibacterial Therapy; Broad-Spectrum Antibacterial Therapy; Drug-Resistant Bacterial Therapies; Drug Discovery; Penicillin Alternatives. Intellectual Property & Development Status: Patent pending.
|Original language||English (US)|
|State||Published - Jan 2020|